A recent CIBMTR study in myelodysplastic syndrome showed that the presence of TP53 mutation was associated with an approximately twofold increased risk in post-HCT mortality (HR = 1.71, p < 0.001)20; this was not modified by conditioning regimen intensity. The gene discussed is TP53; the disease is myelodysplastic syndrome.